Navigation Links
China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results

HAIKOU CITY, China, May 11 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

    First Quarter Highlights
    -- Revenue increased 16% to $15.1 million from $13.0 million in the first
       quarter of fiscal 2009
    -- Gross profit grew 3% to $6.1 million from $5.9 million in the first
       quarter of fiscal 2009
    -- Income from operations rose 19% to $4.8 million from $4.1 million in
       the 2009 period
    -- Net income climbed 17% to $4.3 million, or $0.10 per diluted share,
       from $3.7 million, or $0.09 per diluted share a year ago

"We are pleased to report a solid start to 2010 with healthy revenue and net income growth, in the first quarter," said China Pharma's President and CEO, Ms. Zhilin Li. "The strong revenue increase and healthy profit margins were partly driven by a continued increase in demand for our existing products and the successful launch of new products in the last twelve months. We look forward to accelerating this growth trajectory by increasing market penetration of key existing products and introducing new products to increase revenues and support a stable gross margin."

First Quarter Results

First quarter 2010 revenues grew 16% to $15.1 million from $13.0 million in the first quarter 2009. Key growth drivers included a 32% increase in the Company's anti-viral/infective and respiratory products to $5.4 million. Sales of digestive products rose by 291% to $1.7 million, mainly due to contribution from new products, Tiopronin and Omeprazole, launched in second quarter and fourth quarter of 2009, respectively. The two products generated sales of $1.1 million in the quarter and are expected to drive further sales growth in this category during 2010. Sales of the Company's central nervous system (CNS) and Cerebro & Vascular products were $5.3 million in the quarter, unchanged as compared to last year.

Gross profit for the three months ended March 31, 2010 increased to $6.1 million from $5.9 million in the comparable period last year. Gross profit margin for the first quarter was 40.6% as compared to 45.6% in the previous year quarter. The decrease in gross margin was largely a result of a product mix that included more antibiotic and mature products, which typically yield lower average margin. The Company expects stable gross margin in future quarters supported by an improving product mix and potential new product launches.

Total operating expenses decreased 30% to $1.3 million for the three months ended March 31, 2010 from $1.9 million in the same period last year, primarily due to a change in the Company's estimate for bad debt reserve in the third quarter of 2009. Bad debt expenses fell to $0.1 million in the first quarter of 2010 from $0.8 million in the same period last year. Excluding the bad debt expense, operating expenses rose 13% due higher year-over-year general and administrative expenses reflecting increased amortization expenses.

Operating income grew 19% to $4.8 million for the three months ended March 31, 2010 from $4.1 million in the comparable period a year ago. Operating margin improved by 69 basis points to 32.0% from a year ago, primarily due to the significant reduction in bad debt expenses.

Income tax expense was $0.5 million, up from $0.4 million in the previous year. The Company expects full year 2010 tax rate to be in the 11% range.

Net income for the three months ended March 31, 2010 increased 17% to $4.3 million from $3.7 million in the previous year. Net margin improved to 28.5% to 28.3% in the prior year period. Diluted earnings per share grew 15% year-over-year to $0.10.

Financial Condition

As of March 31, 2010, the Company had cash and cash equivalents of $4.8 million, which represented 4.4% of total assets, as compared to $3.6 million, or 3.6% of total assets, as of December 31, 2009. Year-over-year, working capital increased to $66 million from $61 million while the current ratio rose slightly to 7.1x, reflecting the Company's continued financial health.

Accounts receivable balance rose slightly to $52.5 million from $51.2 million at the end of 2009. China Pharma's management continues to be highly focused on improving accounts receivable collection to further strengthen operating cash flow.

For the three months ended March 31, 2010, cash flow from operating activities was $1.1 million, little changed as compared to the same period in 2009. The flattish operating cash flow trend reflected an improvement in cash collection from accounts receivables, offset by an increase in inventory level, in anticipation of sales demand growth, and advances to suppliers.

Financial Guidance

China Pharma is reiterating 2010 revenue growth guidance of 20% to 25%. Similar to prior years, the first quarter is typically one of the slowest sales periods and the Company anticipates stronger top-line growth during second half of the fiscal year due to seasonality of the product portfolio. The Company expects its central nervous system (CNS) and cardiovascular drugs, and the new Tiopronin and Omeprazole products to be among the key growth drivers in the next several quarters.

"We are confident in our 2010 outlook and plan to focus on increasing the market penetration of our new products while advancing our late-stage development pipeline to create new revenue opportunities," added Ms. Li. "We believe implementation of China's unprecedented $124 billion healthcare reform program will be a significant volume driver in the country's pharmaceutical industry. China Pharma is well positioned to be nimble and to proactively engage in market demand-based new product opportunities to drive sustainable long-term growth."

Pipeline Update

As of March 31, 2010, China Pharma had 9 products in active development in its pipeline.

    -- During the first quarter, China Pharma completed the clinical trials
       for candesartan (generic form of Atacand), a front-line
       antihypertensive therapy. The Company's application for production of
       candesartan is currently under SFDA review.
    -- The clinical trial for lipid lowering drug rosuvastatn (a generic form
       of Crestor) is on track to completion. Crestor is one of the largest
       and fastest growing drugs in the world for lowering cholesterol.
    -- The Phase I clinical trial for the novel anti-resistant antibiotic
       combination drug is also progressing on schedule.

Conference Call

The Company will hold a conference call at 8:00 am ET on May 11, 2010 to discuss first quarter 2010 results. Listeners may access the call by dialing 1-866-700-7173 or 1-617-213-8838 for international callers, access code: 73484838. A webcast will also be available through the Company's website at . A replay of the call will be accessible through May 18, 2010 by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 36235935.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

                          - FINANCIAL TABLES FOLLOW -

                           CHINA PHARMA HOLDINGS, INC.

                                                  March 31,       December 31,
                                                    2010              2009
    Current Assets:
      Cash and cash equivalents                  $4,784,582        $3,634,753
      Trade accounts receivable, less
       allowance for doubtful accounts
       of $2,783,291 and $2,718,358,
       respectively                              52,470,644        51,238,339
      Other receivables, less allowance
       for doubtful accounts of $9,965
       and $3,556, respectively                      84,747            78,525
      Advances to suppliers                       2,836,250         1,798,446
      Inventory                                  15,839,393        14,233,073
      Deferred tax assets                           392,210           319,820
    Total Current Assets                         76,407,826        71,302,956
    Advances for purchases of property
     and equipment and intangible assets          4,259,792         3,599,949
    Property and equipment, net of
     accumulated depreciation of
     $2,213,723 and $2,020,462, respectively      6,537,960         6,705,873
    Intangible assets, net of accumulated
     amortization of $1,586,229 and
     $1,359,048, respectively                    20,947,900        19,332,284
    TOTAL ASSETS                               $108,153,478      $100,941,062

    Current Liabilities:
      Trade accounts payable                     $4,243,181        $3,957,923
      Accrued expenses                               47,749            47,435
      Accrued taxes payable                       1,684,337         1,528,691
      Other payables                                 60,242            58,191
      Advances from customers                       903,070         1,037,693
      Other payables - related parties               75,741            75,741
      Short-term notes payable                    3,803,338         3,802,726
    Total Current Liabilities                    10,817,658        10,508,400
    Long-term research and development
     commitments                                         --            36,565
    Total Liabilities                            10,817,658        10,544,965
    Stockholders' Equity:
      Preferred stock, $0.001 par value;
       5,000,000 shares authorized;
       no shares issued or outstanding                   --                --
      Common stock, $0.001 par value;
       95,000,000 shares of
       authorized; 43,393,644 shares and
       42,308,350 shares of common stock
       outstanding, respectively                     43,393            42,308
      Additional paid-in capital                 23,807,653        21,178,114
      Retained earnings                          67,567,522        63,272,868
      Accumulated foreign currency
       translation adjustment                     5,917,252         5,902,807
    Total Stockholders' Equity                   97,335,820        90,396,097
     EQUITY                                    $108,153,478      $100,941,062

                           CHINA PHARMA HOLDINGS, INC.
                            AND COMPREHENSIVE INCOME

                                                 For the Three Months Ended
                                                          March 31,
                                                   2010              2009

    Revenue                                    $15,102,510       $12,991,982
    Cost of revenue                              8,968,302         7,063,227

    Gross profit                                 6,134,208         5,928,755

    Operating expenses:
      Selling expenses                             582,888           602,760
      General and administrative expenses          652,748           488,047
      Bad debt expense                              70,906           774,932
    Total operating expenses                     1,306,542         1,865,739

    Income from operations                       4,827,666         4,063,016

    Other income (expense):
      Interest income                                6,757            10,589
      Interest expense                             (50,490)          (38,236)
    Net other expense                              (43,733)          (27,647)

    Income before income taxes                   4,783,933         4,035,369
    Income tax expense                            (489,279)         (357,722)
    Net income                                   4,294,654         3,677,647

    Other comprehensive income - foreign
     currency translation adjustment                14,445            87,491
    Comprehensive income                        $4,309,099        $3,765,138

    Earnings per Share:
    Basic                                            $0.10             $0.09
    Diluted                                          $0.10             $0.09

                           CHINA PHARMA HOLDINGS, INC.

                                                 For the Three Months Ended
                                                          March 31,
                                                    2010              2009
    Cash Flows from Operating Activities:
      Net income                                $4,294,654        $3,677,648
      Depreciation and amortization                419,903           258,021
      Stock based compensation                      47,624                --
      Changes in assets and liabilities:
        Trade accounts receivable               (1,224,072)       (4,992,389)
        Other receivables                           (6,209)          (46,549)
        Advances to suppliers                   (1,037,525)        1,211,004
        Inventory                               (1,604,046)          (49,800)
        Deferred tax assets                        (72,339)         (122,965)
        Trade accounts payable                     318,952         1,174,251
        Accrued expenses                           (36,265)           (7,723)
        Accrued taxes payable                      155,402           (15,659)
        Other payables                               2,043             2,004
        Advances from customers                   (134,791)           29,292
    Net Cash Provided by Operating Activities    1,123,331         1,117,135

    Cash Flows from Investing Activities:
      Advances for purchases of property
       and equipment and intangible assets      (1,291,216)       (2,376,453)
      Purchase of property and equipment           (58,272)         (523,476)
      Purchase of intangible assets             (1,207,541)               --
    Net Cash Used in Investing Activities       (2,557,029)       (2,899,929)

    Cash Flows from Financing Activity:
      Proceeds from exercise of warrants         2,583,000                --
    Net Cash Provided by Financing Activity      2,583,000                --

    Effect of Exchange Rate Changes on Cash            527             7,527
    Net Increase (Decrease) in Cash              1,149,829        (1,775,267)
    Cash and Cash Equivalents at
     Beginning of Period                         3,634,753         6,927,149
    Cash and Cash Equivalents at End of
     Period                                     $4,784,582        $5,151,882

    Supplemental Cash Flow Information:
      Cash paid for interest                       $50,490           $38,236
      Cash paid for income taxes                   376,727           560,935


    China Pharma Holdings, Inc.
     Phone: +86-898-6681-1730 (China)

    CCG Investor Relations
     Lei Huang, Account Manager
     Phone: +1-646-833-3417 (New York)

     Vivian Chen, Sr. Market Intelligence Exec.
     Phone: +1-646-701-7445 (New York)

SOURCE China Pharma Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):